Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24617297 | 0.81 | LPL (0.32) | UCHL1LPLLIPGP2RX7FFAR1 | |
| SCHEMBL24616944 | 0.79 | LPL (0.37) | LPLLIPGP2RX7FFAR1 | |
| SCHEMBL24616920 | 0.79 | UCHL1 (0.32) | UCHL1LPLLIPGP2RX7FFAR1 | |
| SCHEMBL1674177 | 0.78 | HPGDS (0.35) | P2RX7 | |
| SCHEMBL24617554 | 0.77 | UCHL1 (0.36) | UCHL1 | |
| SCHEMBL20517194 | 0.77 | — | — | |
| SCHEMBL13918170 | 0.76 | — | — | |
| SCHEMBL20225335 | 0.75 | — | — | |
| SCHEMBL19611703 | 0.75 | LIPE (0.32) | LPLLIPGFFAR1 | |
| SCHEMBL32684569 | 0.75 | ESR2 (0.33) | UCHL1LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12351581-B2 | Compounds for FGFR inhibition | COGENT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009079011-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-06-25 | — | — | WO | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | UCHL1 3731/4885AKT1 45/4885AKT2 89/4885 |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | UCHL1 3731/4885AKT1 45/4885AKT2 89/4885 |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | UCHL1 4621/4885AKT1 820/4885AKT2 706/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | UCHL1 3552/4885AKT1 33/4885AKT2 39/4885 |
| US-12351581-B2 | Compounds for FGFR inhibition | FGFR1, FGFR4, FGFR3 | UCHL1 4621/4885AKT1 820/4885AKT2 706/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | UCHL1 3598/4885AKT1 3419/4885AKT2 2388/4885 |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | UCHL1 3152/4885AKT1 20/4885AKT2 12/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | UCHL1 3565/4885AKT1 3336/4885AKT2 2968/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | UCHL1 4629/4885AKT1 1747/4885AKT2 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.